Research Grant: Multiple Myeloma (Belantamab KMafodotin)

Combination Therapies:
Belamaf in combination with novel treatment options (e.g. CeLMoDs) in late-stage development in Multiple Myeloma where there is no ongoing research
• Induction with T-cell engagers followed by low-dose belamaf maintenance therapy
• Belamaf as bridging therapy prior to T-Cell engagers (e.g. CAR-T).
• Innovative combinations with a strong scientific rationale aimed at addressing areas of high unmet need.

Additional Therapeutic Targets
BCMA expressing malignancies (advanced amyloidosis in Cardiac 3b in both ND and RR ALA).

Pipeline asset(s) proposals may be considered where there is strong rational and data delivery aligns with clinical development of the asset.